Vascular endothelial growth factor expression correlates with hematogenous metastasis and prognosis in colorectal carcinoma

Kang, Soyoung; Maeda, Koki; Chung, Yun Jae; Onoda, N; Ogawa, Yoshitsugu; Takatsuka, Satoshi; Ogawa, Mikako; Sawada, Tetsuji; Nakata, Bunzo; Nishiguchi, Yukio; Ikehara, Teruyuki; Okuno, Masahiro; Sowa, Michio

doi:10.3892/or.4.2.381

Cited by 18 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated VEGF levels are associated with the progression of a variety of tumors and correlated to the outcome of cancer treatment (36,37). To date, numerous attempts to block the activity of VEGF have been made, including the use of antibodies (38), soluble VEGF receptors (39), VEGF receptor antagonists (40), or degradation of the VEGF message through the use of antisense oligonucleotides (41) or by RNA interference (42,43).…”

Section: Discussionmentioning

confidence: 99%

Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist

Olenyuk

Zhang

Klco

et al. 2004

Proc. Natl. Acad. Sci. U.S.A.

205

180

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist

Olenyuk

Zhang

Klco

et al. 2004

Proc. Natl. Acad. Sci. U.S.A.

205

180

View full text Add to dashboard Cite

“…VEGF has been reported to be expressed in gastrointestinal cancers, while its receptor is present on the vessels in stromal tissue adjacent to such tumors, suggesting that VEGF plays a role in tumor angiogenesis (Brown et al, 1993). VEGF expression was found to correlate strongly with liver metastasis and hematogenous recurrence of gastrointestinal carcinomas, and we have proposed that it might be useful in predicting the risk of recurrence of this type of cancers (Maeda et al, 1996;Kang et al, 1997).…”

mentioning

confidence: 84%

“…Immunostaining for VEGF was considered positive when unequivocal staining of cell membrane or cytoplasm was observed in more than 10% of tumor cells, as previously described (Maeda et al, 1996;Kang et al, 1997).…”

Section: Immunohistochemical Study Of P53 and Vegfmentioning

confidence: 99%

Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis

et al. 1997

View full text Add to dashboard Cite

Recent studies have demonstrated that the p53 tumor suppressor gene plays an important role in controlling tumor angiogenesis. We examined the expression of p53 and vascular endothelial growth factor (VEGF), a well-characterized angiogenic inducer, together with microvessel density to investigate the role of p53 in the regulation of angiogenesis and its clinical significance in human colorectal carcinoma. Surgically resected specimens of 163 colorectal carcinomas were studied by immunohistochemical staining for p53 protein, VEGF and factor VIII-related antigen. Positive p53 protein accumulation and VEGF expression was found in 41.7% and 49.1% of tumors, respectively. p53 and VEGF staining status was identical in 65.6% of tumors. The incidence of p53-or VEGF-positive tumors was significantly higher in patients with venous invasion and liver metastases than in those without. The microvessel count (MVC) in p53-or VEGF-positive tumors was significantly higher than that in negative tumors, and MVC in both p53-and VEGF-positive tumors was significantly higher than that in the other subgroups. Neither synchronous nor metachronous hepatic metastases were found in patients with p53-and VEGF-negative tumors, while 52.2% of patients with both-positive tumors had liver metastases and had a poorer prognosis than those with both-negative tumors. Our findings suggest the presence of a p53-VEGF pathway regulating tumor angiogenesis in human colorectal carcinoma. Combined analysis of p53 and VEGF expression might be useful for predicting the occurrence of liver metastasis in patients with this disease.

show abstract

“…There have been several recent reports of the analysis of VEGF in colorectal cancer, all of which used immunohistochemistry on formalin-fixed, waxembedded sections and showed that VEGF is primarily localized to tumour cells. In the largest study of 175 colorectal carcinomas (stage 0,7;I,24;II,48;III,59;IV,37), the presence of VEGF correlated with increasing tumour stage and was associated with decreased overall survival (P < 0.05) and decreased disease-free survival (P < 0.01) (Kang et al, 1997). However, it was not an independent prognostic factor.…”

Section: Vascular Endothelial Growth Factormentioning

confidence: 94%

Tumour markers of prognosis in colorectal cancer

1998

View full text Add to dashboard Cite

Vascular endothelial growth factor expression correlates with hematogenous metastasis and prognosis in colorectal carcinoma

Cited by 18 publications

References 0 publications

Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist

Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist

Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis

Tumour markers of prognosis in colorectal cancer

Contact Info

Product

Resources

About